中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2013年
10期
1311-1314
,共4页
翟斐%杨秉芬%曹志红%安红娟%王若%程小星
翟斐%楊秉芬%曹誌紅%安紅娟%王若%程小星
적비%양병분%조지홍%안홍연%왕약%정소성
分枝杆菌,结核%抗原%结核/治疗%表位,T淋巴细胞
分枝桿菌,結覈%抗原%結覈/治療%錶位,T淋巴細胞
분지간균,결핵%항원%결핵/치료%표위,T림파세포
Mycobacterium tuberculosis%Antigens%Tuberculosis/therapy%Epitopes,T-lymphocyte
目的 寻找结核分枝杆菌抗原Rv2608的T细胞反应多肽,以用于结核病治疗或辅助治疗.方法 采用生物信息学方法预测Rv2608的T细胞表位,筛选表位集中、亲和力较强、理化性质稳定的长链多肽,进行化学合成,应用酶联免疫斑点技术检测多肽刺激活动性结核病患者免疫细胞分泌IFN-γ的能力.结果 预测并筛选出Rv2608长链多肽4条,ELISPOT结果表明4条多肽可以激活部分活动性结核病患者的免疫细胞,其中Rv2608p3的免疫激活效率最高.结论 软件预测与初步鉴定结果具有一致性,Rv2608p3可用于结核病治疗性疫苗的进一步研究.
目的 尋找結覈分枝桿菌抗原Rv2608的T細胞反應多肽,以用于結覈病治療或輔助治療.方法 採用生物信息學方法預測Rv2608的T細胞錶位,篩選錶位集中、親和力較彊、理化性質穩定的長鏈多肽,進行化學閤成,應用酶聯免疫斑點技術檢測多肽刺激活動性結覈病患者免疫細胞分泌IFN-γ的能力.結果 預測併篩選齣Rv2608長鏈多肽4條,ELISPOT結果錶明4條多肽可以激活部分活動性結覈病患者的免疫細胞,其中Rv2608p3的免疫激活效率最高.結論 軟件預測與初步鑒定結果具有一緻性,Rv2608p3可用于結覈病治療性疫苗的進一步研究.
목적 심조결핵분지간균항원Rv2608적T세포반응다태,이용우결핵병치료혹보조치료.방법 채용생물신식학방법예측Rv2608적T세포표위,사선표위집중、친화력교강、이화성질은정적장련다태,진행화학합성,응용매련면역반점기술검측다태자격활동성결핵병환자면역세포분비IFN-γ적능력.결과 예측병사선출Rv2608장련다태4조,ELISPOT결과표명4조다태가이격활부분활동성결핵병환자적면역세포,기중Rv2608p3적면역격활효솔최고.결론 연건예측여초보감정결과구유일치성,Rv2608p3가용우결핵병치료성역묘적진일보연구.
Objective To discover T cell reactive peptides of mycobacterium tuberculosis antigen Rv2608 for treatment or adjuvant treatment for tuberculosis.Methods The T cell epitopes of Rv2608 were predicted by bioinformatics.The long-chain peptides were screened with strong affinity with HLA-A0201,HLA-A1101,and HLA-A2402.The physical and chemical characters of the peptides were predicted.The stable and hydrophilic peptides for chemical synthesis were selected.The T cell reactivity of the peptides in patients with active tuberculosis was detected by ELISPOT.The results were compared with the clinical diagnosis kits TSPOT.TB.Results Four peptides of Rv2608 were predicted and screened,and they could be active T cells of patients with active TB.Rv2608p3 was the most efficient to prime the T cell response.Conclusions Software prediction was consistent with the result of ELISPOT.Rv2608p3 might be the candidate for therapeutic vaccine for tuberculosis.